AstraZeneca PLC A1ZN34.SA Stock
AstraZeneca PLC Price Chart
AstraZeneca PLC A1ZN34.SA Financial and Trading Overview
AstraZeneca PLC stock price | 58.86 BRL |
Previous Close | 58.75 BRL |
Open | 0 BRL |
Bid | 58.68 BRL x N/A |
Ask | 60.48 BRL x N/A |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 64.44 BRL |
Volume | 0 BRL |
Avg. Volume | 759 BRL |
Market Cap | 1.11T BRL |
Beta (5Y Monthly) | 0.194636 |
PE Ratio (TTM) | 24.367348 |
EPS (TTM) | 3.23 BRL |
Forward Dividend & Yield | 1.26 (2.14%) |
Ex-Dividend Date | February 23, 2023 |
1y Target Est | N/A |
A1ZN34.SA Valuation Measures
Enterprise Value | 1.14T BRL |
Trailing P/E | 24.367348 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 25.35357 |
Price/Book (mrq) | 31.1308 |
Enterprise Value/Revenue | 26.008 |
Enterprise Value/EBITDA | 76.595 |
Trading Information
AstraZeneca PLC Stock Price History
Beta (5Y Monthly) | 0.194636 |
52-Week Change | 11.88% |
S&P500 52-Week Change | 20.43% |
52 Week High | 64.44 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 61.08 BRL |
200-Day Moving Average | 57.06 BRL |
A1ZN34.SA Share Statistics
Avg. Volume (3 month) | 759 BRL |
Avg. Daily Volume (10-Days) | 407 BRL |
Shares Outstanding | 9.3B |
Float | 18.59B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.0020% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 2.9 |
Trailing Annual Dividend Yield | 4.93% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.48360002 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 10.73% |
Operating Margin (ttm) | 23.09% |
Gross Margin | 84.30% |
EBITDA Margin | 33.95% |
Management Effectiveness
Return on Assets (ttm) | 6.42% |
Return on Equity (ttm) | 13.05% |
Income Statement
Revenue (ttm) | 43.84B BRL |
Revenue Per Share (ttm) | 2.35 BRL |
Quarterly Revenue Growth (yoy) | -4.50% |
Gross Profit (ttm) | 35.73B BRL |
EBITDA | 14.89B BRL |
Net Income Avi to Common (ttm) | 4.7B BRL |
Diluted EPS (ttm) | 2.45 |
Quarterly Earnings Growth (yoy) | 367.09% |
Balance Sheet
Total Cash (mrq) | 6.46B BRL |
Total Cash Per Share (mrq) | 0.35 BRL |
Total Debt (mrq) | 32.47B BRL |
Total Debt/Equity (mrq) | 90.68 BRL |
Current Ratio (mrq) | 0.896 |
Book Value Per Share (mrq) | 1.917715 |
Cash Flow Statement
Operating Cash Flow (ttm) | 9.71B BRL |
Levered Free Cash Flow (ttm) | 9.69B BRL |
Profile of AstraZeneca PLC
Country | Brazil |
State | N/A |
City | Cambridge |
Address | 1 Francis Crick Avenue |
ZIP | CB2 0AA |
Phone | 44 20 3749 5000 |
Website | https://www.astrazeneca.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 83500 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Q&A For AstraZeneca PLC Stock
What is a current A1ZN34.SA stock price?
AstraZeneca PLC A1ZN34.SA stock price today per share is 58.86 BRL.
How to purchase AstraZeneca PLC stock?
You can buy A1ZN34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AstraZeneca PLC?
The stock symbol or ticker of AstraZeneca PLC is A1ZN34.SA.
Which industry does the AstraZeneca PLC company belong to?
The AstraZeneca PLC industry is Drug Manufacturers-General.
How many shares does AstraZeneca PLC have in circulation?
The max supply of AstraZeneca PLC shares is 18.63B.
What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?
AstraZeneca PLC PE Ratio is 18.22291000 now.
What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?
AstraZeneca PLC EPS is 3.23 BRL over the trailing 12 months.
Which sector does the AstraZeneca PLC company belong to?
The AstraZeneca PLC sector is Healthcare.